Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALK-001 Extension Study in Stargardt Disease
NCT04239625Phase 2Active, not recruiting
- Sponsor
- Alkeus Pharmaceuticals, Inc.
- Start
- Dec 2019
- Primary completion
- Dec 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gildeuretinol in Stargardt disease (STGD), sponsored by Alkeus Pharmaceuticals, Inc. Primary endpoints: Adverse Events at 24 months and Pharmacokinetics at 24 months. Started Dec 2019; status: active, not recruiting.
02
Drugs
gildeuretinol
03
Conditions
Stargardt disease (STGD)
Beyond the preview
Go deeper on NCT04239625.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04239625.